Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective

10.1186/s12885-018-4223-y

Saved in:

Bibliographic Details
Main Authors:	Tan, P.-T, Aziz, M.I.A, Pearce, F, Lim, W.-T, Wu, D.B.-C, Ng, K
Other Authors:	DUKE-NUS MEDICAL SCHOOL
Format:	Article
Published:	2020
Subjects:	afatinib cisplatin epidermal growth factor receptor pemetrexed antineoplastic agent advanced cancer Article cancer chemotherapy cancer growth comparative effectiveness controlled study cost effectiveness analysis death drug cost drug effect drug efficacy drug response drug safety EGFR gene gene mutation human major clinical study medical decision making multiple cycle treatment non small cell lung cancer overall survival phase 3 clinical trial progression free survival quality of life randomized controlled trial sensitivity analysis Singapore survival rate treatment outcome cancer staging clinical trial cost benefit analysis genetics health care cost lung tumor metastasis mortality mutation pathology prognosis Afatinib Antineoplastic Combined Chemotherapy Protocols Carcinoma, Non-Small-Cell Lung Cisplatin Cost-Benefit Analysis ErbB Receptors Health Care Costs Humans Lung Neoplasms Mutation Neoplasm Metastasis Neoplasm Staging Pemetrexed Prognosis Treatment Outcome
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/181206
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-181206
record_format	dspace
spelling	sg-nus-scholar.10635-1812062023-09-13T21:21:28Z Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective Tan, P.-T Aziz, M.I.A Pearce, F Lim, W.-T Wu, D.B.-C Ng, K DUKE-NUS MEDICAL SCHOOL afatinib cisplatin epidermal growth factor receptor pemetrexed afatinib antineoplastic agent cisplatin epidermal growth factor receptor pemetrexed advanced cancer Article cancer chemotherapy cancer growth comparative effectiveness controlled study cost effectiveness analysis death drug cost drug effect drug efficacy drug response drug safety EGFR gene gene mutation human major clinical study medical decision making multiple cycle treatment non small cell lung cancer overall survival phase 3 clinical trial progression free survival quality of life randomized controlled trial sensitivity analysis Singapore survival rate treatment outcome cancer staging clinical trial cost benefit analysis genetics health care cost lung tumor metastasis mortality mutation non small cell lung cancer pathology prognosis Afatinib Antineoplastic Combined Chemotherapy Protocols Carcinoma, Non-Small-Cell Lung Cisplatin Cost-Benefit Analysis ErbB Receptors Health Care Costs Humans Lung Neoplasms Mutation Neoplasm Metastasis Neoplasm Staging Pemetrexed Prognosis Singapore Treatment Outcome 10.1186/s12885-018-4223-y BMC Cancer 18 1 352 2020-10-27T10:12:02Z 2020-10-27T10:12:02Z 2018 Article Tan, P.-T, Aziz, M.I.A, Pearce, F, Lim, W.-T, Wu, D.B.-C, Ng, K (2018). Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective. BMC Cancer 18 (1) : 352. ScholarBank@NUS Repository. https://doi.org/10.1186/s12885-018-4223-y 14712407 https://scholarbank.nus.edu.sg/handle/10635/181206 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	afatinib cisplatin epidermal growth factor receptor pemetrexed afatinib antineoplastic agent cisplatin epidermal growth factor receptor pemetrexed advanced cancer Article cancer chemotherapy cancer growth comparative effectiveness controlled study cost effectiveness analysis death drug cost drug effect drug efficacy drug response drug safety EGFR gene gene mutation human major clinical study medical decision making multiple cycle treatment non small cell lung cancer overall survival phase 3 clinical trial progression free survival quality of life randomized controlled trial sensitivity analysis Singapore survival rate treatment outcome cancer staging clinical trial cost benefit analysis genetics health care cost lung tumor metastasis mortality mutation non small cell lung cancer pathology prognosis Afatinib Antineoplastic Combined Chemotherapy Protocols Carcinoma, Non-Small-Cell Lung Cisplatin Cost-Benefit Analysis ErbB Receptors Health Care Costs Humans Lung Neoplasms Mutation Neoplasm Metastasis Neoplasm Staging Pemetrexed Prognosis Singapore Treatment Outcome
spellingShingle	afatinib cisplatin epidermal growth factor receptor pemetrexed afatinib antineoplastic agent cisplatin epidermal growth factor receptor pemetrexed advanced cancer Article cancer chemotherapy cancer growth comparative effectiveness controlled study cost effectiveness analysis death drug cost drug effect drug efficacy drug response drug safety EGFR gene gene mutation human major clinical study medical decision making multiple cycle treatment non small cell lung cancer overall survival phase 3 clinical trial progression free survival quality of life randomized controlled trial sensitivity analysis Singapore survival rate treatment outcome cancer staging clinical trial cost benefit analysis genetics health care cost lung tumor metastasis mortality mutation non small cell lung cancer pathology prognosis Afatinib Antineoplastic Combined Chemotherapy Protocols Carcinoma, Non-Small-Cell Lung Cisplatin Cost-Benefit Analysis ErbB Receptors Health Care Costs Humans Lung Neoplasms Mutation Neoplasm Metastasis Neoplasm Staging Pemetrexed Prognosis Singapore Treatment Outcome Tan, P.-T Aziz, M.I.A Pearce, F Lim, W.-T Wu, D.B.-C Ng, K Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective
description	10.1186/s12885-018-4223-y
author2	DUKE-NUS MEDICAL SCHOOL
author_facet	DUKE-NUS MEDICAL SCHOOL Tan, P.-T Aziz, M.I.A Pearce, F Lim, W.-T Wu, D.B.-C Ng, K
format	Article
author	Tan, P.-T Aziz, M.I.A Pearce, F Lim, W.-T Wu, D.B.-C Ng, K
author_sort	Tan, P.-T
title	Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective
title_short	Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective
title_full	Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective
title_fullStr	Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective
title_full_unstemmed	Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective
title_sort	cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic egfr mutation positive non-small-cell lung cancer from the singapore healthcare payer's perspective
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/181206
_version_	1779152777770958848

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective

Similar Items